

A LIFE IN MOTION



DHARMA BIOSCIENCE



Stage: preclinical

Market size: \$20 Bn

Growth Drivers

Advanced technologies
Prevalence growth rates
Biotech investment
Innovation

Use of proceeds

Pre-clinical POC
Pre-clinical POF
Consolidate IP portfolio
Regulatory affairs

Team

Gastón Topol, President, CMO

MSK LATAM leader
Orthopedic Medicine
Texas Univ. Advisor

Franco Cescotti, CEO

IAE Business school
Máster Univ. Salamanca

Diego O. Croci, CSO

Research CONICET
Associate Prof. UNCuyo

Andrés Graziosi

Chairman of Board



Contact info.

- <https://dharmabioscience.com>
- fcescotti@dharmabioscience.com
- [dharma-bioscience](https://www.linkedin.com/company/dharma-bioscience/)

Dharma is a biotech startup aimed to spearhead the next generation of regenerative treatments for musculoskeletal diseases.

Opportunity

Osteoarthritis (OA) is the first cause of permanent disability, and still **has no cure**. Current available treatments merely provide temporary relief until joint replacement surgery.

In this scenario, Dharma represents a unique opportunity to investors, as the predicted market size for OA is set to reach \$20 billion by 2030. **With a local injection into the joint, Dharma provides a simple, safe, and effective treatment for OA.**


Our Solution



Innovative **modified-miRs** promoting chondrocyte reprogramming and tissue regeneration.

OA KNEE

Encouraging results:



● Dharma's modified miRs
● Control

Our trials utilized a unique **human ex vivo model** designed to mimic the key features of severe osteoarthritis. This model employed **dysfunctional chondrocyte cells**, isolated from the knees of patients with advanced OA, and maintained in an **inflammatory environment**.

Why Dharma?



No surgery
Easy application



Tissue regeneration



Long term effect

Dharma's vision is to bring healing to patients all around the world through microRNAs new therapeutics